Stock Market Reviews

VERA (Vera Therapeutics, Inc.) News

Get the latest news, insights, and market updates on VERA (Vera Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Analysts Bullish on Vera Therapeutics (VERA) Amid New Commercial Chief Appointment
  Vera Therapeutics Inc. (NASDAQ:VERA) is one of the 13 hot stocks to buy with the highest upside potential. As of February 13, nearly 90% of analysts who cover the stock have assigned a Buy or equivalent rating. The consensus 1-year median price target of $73 implies a 76% upside. Earlier, on January 28, Vera Therapeutics […]
  Feb 19, 2026 - $VERA
• Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA)
  Vera Therapeutics (NASDAQ:VERA) is one of the 17 biotechnology stocks with more than 50% upside. On January 27, Anupam Rama of JPMorgan maintained an Overweight rating on Vera Therapeutics (NASDAQ:VERA) with a $96 price target. His estimates imply upside of more than 127%. Rama believes the shares offer strong upside potential from the current trading […]
  Feb 16, 2026 - $VERA
• Vera Therapeutics, Inc. (VERA): A Bull Case Theory
  We came across a bullish thesis on Vera Therapeutics, Inc. on Valueinvestorsclub.com by yarak775. In this article, we will summarize the bulls’ thesis on VERA. Vera Therapeutics, Inc.’s share was trading at $45.11 as of January 28th. Vera Therapeutics (VERA) is a clinical-stage biotechnology company focused on developing biologic therapies for autoimmune diseases, with its investment case centered almost entirely […]
  Feb 7, 2026 - $VERA
• Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Ind
  Feb 6, 2026 - $VERA
• Vera Therapeutics Readies Atacicept Launch As New CCO Joins, Valuation Lags
  Vera Therapeutics appointed Matt Skelton as Chief Commercial Officer to guide commercialization efforts for its lead IgA nephropathy candidate, atacicept. The move comes as atacicept holds Breakthrough Therapy Designation and is under FDA Priority Review, signaling preparation for a potential commercial launch. The leadership change marks a shift for Vera Therapeutics toward operating as a commercial stage biotech company. For investors tracking NasdaqGM:VERA, the appointment lands at a...
  Feb 3, 2026 - $VERA
• Is Vera’s New Commercial Chief And Atacicept Launch Push Altering The Investment Case For Vera Therapeutics (VERA)?
  Vera Therapeutics recently appointed Matt Skelton as Chief Commercial Officer, effective January 28, 2026, elevating him from his prior role as Executive Vice President, Commercial to lead preparations for the potential launch of its lead IgA nephropathy therapy, atacicept, which is under FDA Priority Review with Breakthrough Therapy Designation. This hire underscores Vera’s move from a purely clinical-focused organization toward building a full commercial infrastructure around atacicept,...
  Feb 3, 2026 - $VERA
• Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential?
  Vera Therapeutics Inc. (NASDAQ:VERA) is one of the best high short interest stocks with biggest upside potential. Earlier on December 19, Bank of America raised its price target for Vera Therapeutics from $48 to $66 while maintaining a Buy rating due to an increased peak revenue forecast for its lead IgAN drug from $1.7 billion […]
  Jan 30, 2026 - $VERA
• Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
  BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. “We are pleased to welcome Matt to the executive
  Jan 28, 2026 - $VERA
• Clinical Success Lifts Vera (VERA) Shares, Boosting Fund Returns
  Voya Investment Management’s Voya MidCap Opportunities Fund released its Q4 2025 investor letter, titled “Seeking a More Favorable Risk/Return Trade-off”, outlining a quarter marked by solid market gains but relative fund underperformance. A copy of the letter can be downloaded here. During the quarter, the Fund underperformed its benchmark, the Russell Mid Cap Growth Index, […]
  Jan 23, 2026 - $VERA
• Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept
  Vera Therapeutics, Inc. (NASDAQ:VERA) is among the 14 best booming stocks to buy right now. On January 7, the company announced that the U.S. Food and Drug Administration (FDA) had accepted Atacicept’s Biologics License Application (BLA) for priority review to treat adult patients of immunoglobulin A nephropathy (IgAN). The application was submitted under the Accelerated […]
  Jan 15, 2026 - $VERA